Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
15245 Shady Grove Road 20850
Rockville, MD, US
Rockville, MD, US
CEO
J. J. Finkelstein
Website
regenerx.com
IPO
2003-10-07
CIK 707511 ISIN US75886X3061
Description
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
28
Beta
4.73
Float Shares
836.3K
Free Float %
55.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +20.00% | +20.00% | +100.00% | +200.00% | +100.00% | +200.00% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-878.30
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.0% Q1'23: 0.0% (vs Q1'22)
-
EPS growth Biotechnology: +29.7%-7,094.2% Q1'23: +10.0% (vs Q1'22)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,199.3% Q1'23: -986.6% (vs Q1'22)
-
EBIT margin Biotechnology: +0.0%-1,826.5% Q1'23: -1,589.4% (vs Q1'22)
-
ROIC Biotechnology: -16.1%— Q1'23: +51.9% (vs Q1'22)
-
Share dilution Biotechnology: -3.4%+3.6% Q1'23: 0.0% (vs Q1'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.03× Q1'23: -1.23× (vs Q1'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
|---|---|---|
| Revenue |
56.7K
est: 53.5K (+5.9%)
|
69.7K
est: 50.0K (+39.3%)
|
| EBITDA |
559.0K
est: -35.0K (+1,697.5%)
|
-1.90M
est: -32.7K (-5,721.9%)
|
| EBIT |
556.0K
est: -53.5K (+1,139.2%)
|
-1.91M
est: -50.0K (-3,712.0%)
|
| Net Income |
286.5K
|
-1.99M
|
| SGA |
1.36M
est: 970.7K (+39.8%)
|
1.31M
est: 907.2K (+44.6%)
|
| EPS |
0.00
|
-0.02
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-823.7K
OE per share TTM
-0.01
Owner's Yield
-956.73%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
38.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (formerly known as Digital Aria Co., Ltd.) | 25.08M | 23.50% | 25.08M | — | 25.08M | 10.00 | CO | Republic of Korea | 2014-09-03 | ↗ |
| 2 | Digital Aria Co., Ltd. | 25.08M | 23.50% | 25.08M | — | 25.08M | 10.00 | CO | Republic of Korea | 2014-03-17 | ↗ |
| 3 | G-treeBNT Co., Ltd. | 19.58M | 19.30% | 19.58M | — | 19.58M | 10.00 | CO | Republic of Korea | 2015-04-01 | ↗ |
| 4 | Defiante Farmaceutica Unipessoal, L.d.a. | 4.26M | 15.90% | 232.81M | 4.26M | — | 4.26M | CO | Italy | 2002-03-12 | ↗ |
| 5 | Sigma-Tau Finanziaria SpA | 4.26M | 15.90% | 232.81M | 4.26M | — | 4.26M | CO | Italy | 2002-03-12 | ↗ |
| 6 | ###-##-####) | 248.7K | 2.92% | — | — | 248.7K | — | IN | United States of America | 1994-02-14 | ↗ |
| 7 | 04-2507163) | 248.7K | 2.92% | 7.3K | — | 248.7K | — | HC | Commonwealth of Massachusetts | 1994-02-14 | ↗ |
| 8 | INVESCO Funds Group, Inc. | — | 0.00% | — | — | — | — | HC | State of Delaware | 1995-02-07 | ↗ |
| 9 | INVESCO North American Group, Ltd. | — | 0.00% | — | — | — | — | HC | England | 1995-02-07 | ↗ |
| 10 | INVESCO North American Holdings, Inc. | — | 0.00% | — | — | — | — | HC | State of Delaware | 1995-02-07 | ↗ |
| 11 | INVESCO PLC | — | 0.00% | — | — | — | — | HC | England | 1995-02-07 | ↗ |
| 12 | INVESCO, Inc. | — | 0.00% | — | — | — | — | HC | State of Delaware | 1995-02-07 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
2.14M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,140,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-03 | Essetifin SPA | 10% Owner | J-Other | A | Common Stock Warrant (right to buy) | 3,750,000 | 0.02 | 75.0K | 3,750,000 | — | ↗ |
| 2022-05-17 | Noseda Alessandro | Director | A-Award | A | Stock Option (Right to Buy) | 240,000 | 0.19 | 45.6K | 240,000 | — | ↗ |
| 2022-05-17 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (Right to Buy) | 290,000 | 0.00 | — | 290,000 | — | ↗ |
| 2022-05-17 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (Right to Buy) | 480,000 | 0.00 | — | 480,000 | — | ↗ |
| 2022-05-17 | FINKELSTEIN J J | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2022-05-17 | Elsey R Don | Director | A-Award | A | Stock Option (Right to Buy) | 290,000 | 0.00 | — | 290,000 | — | ↗ |
| 2022-05-17 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 240,000 | 0.00 | — | 240,000 | — | ↗ |
| 2021-12-08 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 130,000 | 0.00 | — | 1,507,793 | — | ↗ |
| 2021-08-02 | Noseda Alessandro | Director | A-Award | A | Stock Option (right to buy) | 240,000 | 0.28 | 67.2K | 240,000 | — | ↗ |
| 2021-08-02 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 290,000 | 0.28 | 81.2K | 290,000 | — | ↗ |
| 2021-08-02 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 480,000 | 0.28 | 134.4K | 480,000 | — | ↗ |
| 2021-08-02 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 0.28 | 168.0K | 600,000 | — | ↗ |
| 2021-08-02 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 290,000 | 0.28 | 81.2K | 290,000 | — | ↗ |
| 2021-08-02 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 240,000 | 0.28 | 67.2K | 240,000 | — | ↗ |
| 2021-06-30 | GOLDSTEIN ALLAN L | Director | P-Purchase | A | Series B Common Stock Warrant (right to buy) | 93,750 | 0.28 | 26.3K | 93,750 | — | ↗ |
| 2021-06-30 | FINKELSTEIN J J | Director / Officer | P-Purchase | A | Series A Common Stock Warrant (right to buy) | 56,250 | 0.24 | 13.5K | 56,250 | — | ↗ |
| 2021-06-30 | CAVAZZA PAOLO | 10% Owner | J-Other | A | Common Stock Warrant (right to buy) | 1,125,000 | 0.28 | 315.0K | 1,125,000 | — | ↗ |
| 2021-06-30 | APTAFIN S P A | — | — | D | Common Stock Warrant (right to buy) | 1,125,000 | 0.28 | 315.0K | 0 | — | ↗ |
| 2020-12-31 | GOLDSTEIN ALLAN L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | GOLDSTEIN ALLAN L | Director | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.36 | — | 0 | — | ↗ |
| 2020-10-15 | FINKELSTEIN J J | Director / Officer | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.36 | — | 0 | — | ↗ |
| 2020-10-15 | Essetifin SPA | 10% Owner | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Bove Mauro | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 20,880 | 0.45 | 9.4K | 20,880 | — | ↗ |
| 2020-06-10 | Noseda Alessandro | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.30 | 60.0K | 200,000 | — | ↗ |
| 2020-06-10 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 0.30 | 75.0K | 250,000 | — | ↗ |
| 2020-06-10 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 400,000 | 0.30 | 120.0K | 400,000 | — | ↗ |
| 2020-06-10 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 0.30 | 150.0K | 500,000 | — | ↗ |
| 2020-06-10 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 0.30 | 75.0K | 250,000 | — | ↗ |
| 2020-06-10 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.30 | 60.0K | 200,000 | — | ↗ |
| 2019-06-12 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 228,000 | 0.00 | — | 1,712,793 | — | ↗ |
| 2019-05-15 | Noseda Alessandro | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.21 | 42.0K | 200,000 | — | ↗ |
| 2019-05-15 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 0.21 | 52.5K | 250,000 | — | ↗ |
| 2019-05-15 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 410,000 | 0.21 | 86.1K | 410,000 | — | ↗ |
| 2019-05-15 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 650,000 | 0.21 | 136.5K | 650,000 | — | ↗ |
| 2019-05-15 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 0.21 | 52.5K | 250,000 | — | ↗ |
| 2019-05-15 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.21 | 42.0K | 200,000 | — | ↗ |
| 2019-05-13 | MCNAY JOSEPH C | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 78,125 | 0.18 | 14.1K | 78,125 | — | ↗ |
| 2019-05-13 | GOLDSTEIN ALLAN L | Director | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-05-13 | FINKELSTEIN J J | Director / Officer | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-05-13 | Essetifin SPA | 10% Owner | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-05-13 | Elsey R Don | Director | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-05-13 | Bove Mauro | Director | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-02-27 | MCNAY JOSEPH C | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 78,125 | 0.18 | 14.1K | 78,125 | — | ↗ |
| 2019-02-27 | GOLDSTEIN ALLAN L | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 15,625 | 0.18 | 2.8K | 15,625 | — | ↗ |
| 2019-02-27 | FINKELSTEIN J J | Director / Officer | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-02-27 | Elsey R Don | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 15,625 | 0.18 | 2.8K | 15,625 | — | ↗ |
| 2019-02-27 | Bove Mauro | Director | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.12 | — | 0 | — | ↗ |
| 2019-02-26 | Essetifin SPA | 10% Owner | J-Other | A | Common Stock Warrant (right to buy) | 3,125,000 | 0.18 | 562.5K | 3,125,000 | — | ↗ |
| 2019-01-06 | MCNAY JOSEPH C | Director | C-Conversion | A | Common Stock | 522,280 | 0.06 | 31.3K | 6,524,122 | — | ↗ |
| 2019-01-06 | GOLDSTEIN ALLAN L | Director | C-Conversion | A | Common Stock | 208,912 | 0.06 | 12.5K | 1,940,793 | — | ↗ |
| 2018-09-27 | Essetifin SPA | 10% Owner | C-Conversion | A | Common Stock | 3,133,681 | 0.06 | 188.0K | 34,989,080 | — | ↗ |
| 2018-09-11 | MCNAY JOSEPH C | Director | C-Conversion | D | Convertible Promissory Note (right to buy) | 2,089,120 | 0.06 | 125.3K | 0 | — | ↗ |
| 2018-09-11 | GOLDSTEIN ALLAN L | Director | C-Conversion | D | Convertible Promissory Note (right to buy) | 229,803 | 0.06 | 13.8K | 0 | — | ↗ |
| 2018-09-11 | Elsey R Don | Director | C-Conversion | D | Convertible Promissory Note (right to buy) | 104,456 | 0.06 | 6.3K | 0 | — | ↗ |
| 2018-07-17 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.21 | 42.0K | 200,000 | — | ↗ |
| 2018-07-17 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.21 | 52.5K | 250,000 | — | ↗ |
| 2018-07-17 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.21 | 52.5K | 250,000 | — | ↗ |
| 2018-07-17 | Elsey R Don | Director | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.21 | 42.0K | 325,000 | — | ↗ |
| 2018-07-17 | Bove Mauro | Director | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.21 | 42.0K | 325,000 | — | ↗ |
| 2018-07-05 | MCNAY JOSEPH C | Director | C-Conversion | A | Common Stock | 1,044,560 | 0.06 | 62.7K | 3,912,722 | — | ↗ |
| 2018-07-05 | GOLDSTEIN ALLAN L | Director | C-Conversion | A | Common Stock | 208,912 | 0.06 | 12.5K | 1,502,078 | — | ↗ |
| 2018-07-05 | FINKELSTEIN J J | Director / Officer | C-Conversion | D | Convertible Promissory Note (right to buy) | 104,456 | 0.06 | 6.3K | 0 | — | ↗ |
| 2018-04-02 | GOLDSTEIN ALLAN L | Director | C-Conversion | D | Convertible Promissory Note (right to buy) | 522,280 | 0.06 | 31.3K | 0 | — | ↗ |
| 2018-03-29 | MCNAY JOSEPH C | Director | C-Conversion | A | Common Stock | 1,044,560 | 0.06 | 62.7K | 2,868,162 | — | ↗ |
| 2018-03-29 | GOLDSTEIN ALLAN L | Director | C-Conversion | A | Common Stock | 522,280 | 0.06 | 31.3K | 1,293,166 | — | ↗ |
| 2018-03-13 | Sinaf S.A. | 10% Owner | S-Sale | D | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2018-03-13 | Essetifin SPA | 10% Owner | P-Purchase | A | Common Stock | 6,348,878 | 0.23 | 1.46M | 31,855,399 | — | ↗ |
| 2018-01-30 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 250,000 | 0.00 | — | 770,886 | — | ↗ |
| 2017-10-19 | MCNAY JOSEPH C | Director | C-Conversion | D | Convertible Promissory Note (right to buy) | 417,824 | 0.15 | 62.7K | 0 | — | ↗ |
| 2017-10-19 | GOLDSTEIN ALLAN L | Director | C-Conversion | A | Common Stock | 292,477 | 0.15 | 43.9K | 974,220 | — | ↗ |
| 2017-10-19 | FINKELSTEIN J J | Director / Officer | C-Conversion | D | Convertible Promissory Note (right to buy) | 125,347 | 0.15 | 18.8K | 0 | — | ↗ |
| 2017-10-13 | Sinaf S.A. | 10% Owner | J-Other | A | Common Stock | 266,667 | 0.15 | 40.0K | 11,649,370 | — | ↗ |
| 2017-09-01 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.28 | 35.0K | 125,000 | — | ↗ |
| 2017-09-01 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 0.28 | 42.0K | 150,000 | — | ↗ |
| 2017-09-01 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.28 | 42.0K | 150,000 | — | ↗ |
| 2017-09-01 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.28 | 35.0K | 125,000 | — | ↗ |
| 2017-09-01 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.28 | 35.0K | 125,000 | — | ↗ |
| 2017-01-31 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 125,000 | 0.00 | — | 681,743 | — | ↗ |
| 2016-12-31 | FINKELSTEIN J J | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-04-19 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 65,000 | 0.00 | — | 806,743 | — | ↗ |
| 2016-04-11 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 60,000 | 0.00 | — | 871,743 | — | ↗ |
| 2016-03-16 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.64 | 64.0K | 100,000 | — | ↗ |
| 2016-03-16 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.64 | 128.0K | 200,000 | — | ↗ |
| 2016-03-16 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.64 | 128.0K | 200,000 | — | ↗ |
| 2016-03-16 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.64 | 64.0K | 100,000 | — | ↗ |
| 2016-03-16 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.64 | 64.0K | 100,000 | — | ↗ |
| 2015-12-31 | FINKELSTEIN J J | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-30 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.36 | 36.0K | 100,000 | — | ↗ |
| 2015-06-30 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 250,000 | 0.36 | 90.0K | 250,000 | — | ↗ |
| 2015-06-30 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 0.36 | 180.0K | 500,000 | — | ↗ |
| 2015-06-30 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.36 | 36.0K | 100,000 | — | ↗ |
| 2015-06-30 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.36 | 36.0K | 100,000 | — | ↗ |
| 2015-03-16 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 125,000 | 0.00 | — | 931,743 | — | ↗ |
| 2015-02-11 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.19 | 19.0K | 100,000 | — | ↗ |
| 2015-02-11 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.19 | 19.0K | 100,000 | — | ↗ |
| 2015-02-11 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.19 | 19.0K | 100,000 | — | ↗ |
| 2015-02-11 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.19 | 19.0K | 100,000 | — | ↗ |
| 2014-09-29 | MCNAY JOSEPH C | Director | D-Return | D | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2014-09-29 | GOLDSTEIN ALLAN L | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2014-09-29 | FINKELSTEIN J J | Director | D-Return | D | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2014-08-29 | G-treeBNT Co., Ltd. | 10% Owner | X-InTheMoney | A | Common Stock | 8,333,333 | 0.12 | 1,000.0K | 19,583,333 | — | ↗ |
| 2014-06-02 | GOLDSTEIN ALLAN L | Director | G-Gift | D | Common Stock | 250,103 | 0.00 | — | 1,056,743 | — | ↗ |
| 2014-04-16 | SAGLIO DANE R | Officer | — | D | Stock Option (right to buy) | 420,000 | 0.21 | 88.2K | 0 | — | ↗ |
| 2014-03-28 | Digital Aria Co., Ltd. | 10% Owner | X-InTheMoney | A | Common Stock | 11,250,000 | 0.12 | 1.35M | 11,250,000 | — | ↗ |
| 2014-03-25 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 0.21 | 25.2K | 120,000 | — | ↗ |
| 2014-03-25 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 450,000 | 0.21 | 94.5K | 450,000 | — | ↗ |
| 2014-03-25 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 0.21 | 105.0K | 500,000 | — | ↗ |
| 2014-03-25 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 0.21 | 25.2K | 120,000 | — | ↗ |
| 2014-03-25 | Bowles L Thompson | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.21 | 12.6K | 60,000 | — | ↗ |
| 2014-03-25 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 0.21 | 31.5K | 150,000 | — | ↗ |
| 2014-03-07 | Digital Aria | 10% Owner | — | D | Purchase Right (Right to buy) | 5,500,000 | 0.15 | 825.0K | 0 | — | ↗ |
| 2014-02-03 | Sinaf S.A. | 10% Owner | J-Other | D | Common Stock | 64,575 | 0.00 | — | 11,584,795 | — | ↗ |
| 2014-01-07 | MCNAY JOSEPH C | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2014-01-07 | GOLDSTEIN ALLAN L | Director / Officer | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2014-01-07 | Bowles L Thompson | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-09-12 | Sinaf S.A. | 10% Owner | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-09-12 | MCNAY JOSEPH C | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-09-12 | GOLDSTEIN ALLAN L | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-09-12 | Elsey R Don | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-09-12 | CAVAZZA PAOLO | 10% Owner | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-09-12 | Bowles L Thompson | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-07-05 | MCNAY JOSEPH C | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-07-05 | GOLDSTEIN ALLAN L | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-07-05 | FINKELSTEIN J J | Director / Officer | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-07-05 | Bowles L Thompson | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-03-29 | MCNAY JOSEPH C | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2013-03-29 | GOLDSTEIN ALLAN L | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.06 | — | 0 | — | ↗ |
| 2012-10-19 | Sinaf S.A. | 10% Owner | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2012-10-19 | MCNAY JOSEPH C | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2012-10-19 | GOLDSTEIN ALLAN L | Director | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2012-10-19 | FINKELSTEIN J J | Director / Officer | A-Award | A | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2012-10-19 | CAVAZZA PAOLO | 10% Owner | P-Purchase | A | Convertible Promissory Note (right to buy) | 0 | 0.15 | — | 0 | — | ↗ |
| 2012-04-03 | MCNAY JOSEPH C | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.16 | 8.0K | 50,000 | — | ↗ |
| 2012-04-03 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.16 | 5.6K | 35,000 | — | ↗ |
| 2012-04-03 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 0.16 | 5.6K | 35,000 | — | ↗ |
| 2012-04-03 | Elsey R Don | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.16 | 8.0K | 50,000 | — | ↗ |
| 2012-04-03 | CROCKFORD DAVID | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 0.16 | 5.6K | 35,000 | — | ↗ |
| 2012-04-03 | Bowles L Thompson | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.16 | 8.0K | 50,000 | — | ↗ |
| 2012-04-03 | Bove Mauro | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.16 | 8.0K | 50,000 | — | ↗ |
| 2012-02-21 | SAGLIO DANE R | Officer | — | D | Stock Option (right to buy) | 150,000 | 0.14 | 21.0K | 0 | — | ↗ |
| 2012-01-24 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Options (right to buy) | 300,000 | 0.14 | 42.0K | 300,000 | — | ↗ |
| 2012-01-24 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Options (right to buy) | 500,000 | 0.14 | 70.0K | 500,000 | — | ↗ |
| 2011-12-12 | SAGLIO DANE R | Officer | — | D | Stock Option (right to buy) | 31,250 | 0.16 | 5.0K | 0 | — | ↗ |
| 2011-12-02 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Options (right to buy) | 80,135 | 0.16 | 12.8K | 80,135 | — | ↗ |
| 2011-12-02 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Options (right to buy) | 80,135 | 0.16 | 12.8K | 80,135 | — | ↗ |
| 2011-12-02 | CROCKFORD DAVID | Officer | A-Award | A | Stock Options (right to buy) | 91,991 | 0.16 | 14.7K | 91,991 | — | ↗ |
| 2011-08-03 | MCNAY JOSEPH C | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.22 | 4.4K | 20,000 | — | ↗ |
| 2011-08-03 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Options (right to buy) | 98,500 | 0.22 | 21.7K | 98,500 | — | ↗ |
| 2011-08-03 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Options (right to buy) | 125,000 | 0.22 | 27.5K | 125,000 | — | ↗ |
| 2011-08-03 | Elsey R Don | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.22 | 4.4K | 20,000 | — | ↗ |
| 2011-08-03 | CROCKFORD DAVID | Officer | A-Award | A | Stock Options (right to buy) | 98,500 | 0.22 | 21.7K | 98,500 | — | ↗ |
| 2011-08-03 | Bowles L Thompson | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.22 | 4.4K | 20,000 | — | ↗ |
| 2011-08-03 | Bove Mauro | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.22 | 4.4K | 20,000 | — | ↗ |
| 2011-01-05 | Sinaf S.A. | 10% Owner | J-Other | D | Common Stock Warrant (right to buy) | 1 | 4.06 | 4.06 | 0 | — | ↗ |
| 2011-01-05 | SIGMA TAU FINANZIARIA SPA | 10% Owner | J-Other | D | Common Stock Warrants (right to buy) | 1 | 2.75 | 2.75 | 0 | — | ↗ |
| 2011-01-05 | CAVAZZA PAOLO | 10% Owner | P-Purchase | A | Common Stock | 1,296,297 | 0.27 | 350.0K | 9,711,407 | — | ↗ |
| 2011-01-05 | CAVAZZA CLAUDIO | 10% Owner | J-Other | A | Common Stock Warrant (right to buy) | 1 | 0.38 | 0.38 | 4 | — | ↗ |
| 2010-12-31 | GOLDSTEIN ALLAN L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-12-31 | FINKELSTEIN J J | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 51,000 | — | ↗ |
| 2010-09-01 | Elsey R Don | Director | A-Award | A | Common Stock Option (right to buy) | 40,000 | 0.28 | 11.2K | 40,000 | — | ↗ |
| 2010-07-14 | MCNAY JOSEPH C | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.27 | 5.4K | 20,000 | — | ↗ |
| 2010-07-14 | Lyons C Neil | Officer | A-Award | A | Stock Options (right to buy) | 98,500 | 0.27 | 26.6K | 98,500 | — | ↗ |
| 2010-07-14 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Options (right to buy) | 98,500 | 0.27 | 26.6K | 98,500 | — | ↗ |
| 2010-07-14 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Options (right to buy) | 125,000 | 0.27 | 33.8K | 125,000 | — | ↗ |
| 2010-07-14 | CROCKFORD DAVID | Officer | A-Award | A | Stock Options (right to buy) | 98,500 | 0.27 | 26.6K | 98,500 | — | ↗ |
| 2010-07-14 | Bowles L Thompson | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.27 | 5.4K | 20,000 | — | ↗ |
| 2010-07-14 | Bove Mauro | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 0.27 | 5.4K | 20,000 | — | ↗ |
| 2010-06-29 | Sinaf S.A. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,415,110 | — | ↗ |
| 2010-06-11 | Lyons C Neil | Officer | P-Purchase | A | Common Stock | 15,000 | 0.28 | 4.3K | 30,000 | — | ↗ |
| 2010-06-10 | Lyons C Neil | Officer | P-Purchase | A | Common Stock | 5,000 | 0.28 | 1.4K | 15,000 | — | ↗ |
| 2010-05-21 | Sinaf S.A. | 10% Owner | — | D | Common Stock Warrant (right to buy) | 96,000 | 0.56 | 53.8K | 0 | — | ↗ |
| 2010-05-21 | CAVAZZA PAOLO | 10% Owner | P-Purchase | A | Common Stock Warrants (right to buy) | 96,000 | 0.56 | 53.8K | 96,000 | — | ↗ |
| 2010-04-15 | Sinaf S.A. | 10% Owner | — | D | Common Stock Warrant (right to buy) | 609,756 | 1.12 | 682.9K | 0 | — | ↗ |
| 2009-12-31 | GOLDSTEIN ALLAN L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-12-31 | FINKELSTEIN J J | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-10-12 | MCNAY JOSEPH C | Director | A-Award | A | Stock Options (right to buy) | 15,000 | 0.76 | 11.4K | 15,000 | — | ↗ |
| 2009-10-12 | Lyons C Neil | Officer | A-Award | A | Stock Options (right to buy) | 75,000 | 0.76 | 57.0K | 75,000 | — | ↗ |
| 2009-10-12 | HINDIN RICHARD J | Director | A-Award | A | Stock Options (right to buy) | 15,000 | 0.76 | 11.4K | 15,000 | — | ↗ |
| 2009-10-12 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Options (right to buy) | 75,000 | 0.76 | 57.0K | 75,000 | — | ↗ |
| 2009-10-12 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Options (right to buy) | 125,000 | 0.76 | 95.0K | 125,000 | — | ↗ |
| 2009-10-12 | Bowles L Thompson | Director | A-Award | A | Stock Options (right to buy) | 15,000 | 0.76 | 11.4K | 15,000 | — | ↗ |
| 2009-10-12 | Bove Mauro | Director | A-Award | A | Stock Options (right to buy) | 15,000 | 0.76 | 11.4K | 15,000 | — | ↗ |
| 2009-10-08 | Chaumiere Consultadoria & Servicos SDC Unipessoal LDA | 10% Owner | P-Purchase | A | Common Stock | 1,219,512 | 0.82 | 1,000.0K | 8,175,110 | — | ↗ |
| 2009-10-08 | CAVAZZA PAOLO | 10% Owner | J-Other | A | Common Stock Warrant (right to buy) | 1 | 1.12 | 1.12 | 1 | — | ↗ |
| 2009-06-02 | Inverlochy Consultadoria & Servicos L.D.A. | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 0.40 | 125.0K | 5,052,582 | — | ↗ |
| 2009-06-02 | HINDIN RICHARD J | Director | S-Sale | D | Common Stock | 625,000 | 0.40 | 250.0K | 967,710 | — | ↗ |
| 2009-06-02 | Chaumiere Consultadoria & Servicos SDC Unipessoal LDA | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 0.40 | 125.0K | 6,955,598 | — | ↗ |
| 2009-06-02 | CAVAZZA PAOLO | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 0.40 | 125.0K | 6,955,598 | — | ↗ |
| 2009-06-02 | CAVAZZA CLAUDIO | 10% Owner | P-Purchase | A | Common Stock | 312,500 | 0.40 | 125.0K | 5,052,582 | — | ↗ |
| 2009-04-13 | Sinaf S.A. | 10% Owner | — | D | Common Stock Warrant (right to buy) | 263,158 | 0.91 | 239.5K | 0 | — | ↗ |
| 2009-04-13 | Chaumiere Consultadoria & Servicos SDC Unipessoal LDA | 10% Owner | P-Purchase | A | Common Stock | 1,052,631 | 0.57 | 600.0K | 6,643,098 | — | ↗ |
| 2009-04-13 | CAVAZZA PAOLO | 10% Owner | P-Purchase | A | Common Stock | 1,052,631 | 0.57 | 600.0K | 6,643,098 | — | ↗ |
| 2009-04-10 | MCNAY JOSEPH C | Director | A-Award | A | Stock Options (right to buy) | 12,036 | 0.57 | 6.9K | 12,036 | — | ↗ |
| 2009-04-10 | Lyons C Neil | Officer | A-Award | A | Stock Options (right to buy) | 116,592 | 0.57 | 66.5K | 116,592 | — | ↗ |
| 2009-04-10 | HINDIN RICHARD J | Director | A-Award | A | Stock Options (right to buy) | 26,624 | 0.57 | 15.2K | 26,624 | — | ↗ |
| 2009-04-10 | GOLDSTEIN ALLAN L | Director | A-Award | A | Stock Options (right to buy) | 104,770 | 0.57 | 59.7K | 104,770 | — | ↗ |
| 2009-04-10 | FINKELSTEIN J J | Director / Officer | A-Award | A | Stock Options (right to buy) | 172,122 | 0.57 | 98.1K | 172,122 | — | ↗ |
| 2009-04-10 | Bowles L Thompson | Director | A-Award | A | Stock Options (right to buy) | 14,765 | 0.57 | 8.4K | 14,765 | — | ↗ |
| 2009-04-10 | Bove Mauro | Director | A-Award | A | Stock Options (right to buy) | 10,732 | 0.57 | 6.1K | 10,732 | — | ↗ |
| 2008-12-31 | GOLDSTEIN ALLAN L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.0K
Shares Outstanding
1.50M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2020 | J.J. Finkelstein, President and Chief Executive Officer | 80.0K | — | — | 95.6K | — | 3.4K | 179.0K | 53.42% | ↗ |
| 2 | 2019 | J.J. Finkelstein, President and Chief Executive Officer | 81.5K | — | — | 103.5K | — | 3.4K | 188.4K | 54.95% | ↗ |
| 3 | 2018 | J.J. Finkelstein, President and Chief Executive Officer | 102.4K | — | — | 38.8K | — | 3.4K | 144.6K | 26.84% | ↗ |
| 4 | 2017 | J.J. Finkelstein, President and Chief Executive Officer | 150.0K | — | — | 31.0K | — | 3.4K | 184.3K | 16.80% | ↗ |
| 5 | 2016 | J.J. Finkelstein, President and Chief Executive Officer | 150.0K | — | — | 91.1K | — | 3.4K | 244.5K | 37.26% | ↗ |
| 6 | 2015 | J.J. Finkelstein, President and Chief Executive Officer | 154.5K | — | — | 127.1K | — | 3.4K | 285.0K | 44.60% | ↗ |
| 7 | 2014 | Dane Saglio, Chief Financial Officer | 72.5K | — | — | 60.2K | — | 58.5K | 191.2K | 31.48% | ↗ |
| 8 | 2014 | J.J. Finkelstein, President and Chief Executive Officer | 110.8K | — | — | 71.6K | — | 3.4K | 185.8K | 38.55% | ↗ |
| 9 | 2013 | J.J. Finkelstein, President and Chief Executive Officer | 65.0K | — | — | — | — | — | 65.0K | 0.00% | ↗ |
| 10 | 2013 | Dane Saglio, Chief Financial Officer | — | — | — | — | — | 57.5K | 57.5K | 0.00% | ↗ |
| 11 | 2012 | J.J. Finkelstein, President and Chief Executive Officer | 62.5K | — | — | 43.2K | — | 22.1K | 127.8K | 33.83% | ↗ |
| 12 | 2010 | J.J. Finkelstein, President and Chief Executive Officer | 299.5K | — | — | 19.4K | — | 18.4K | 337.3K | 5.75% | ↗ |
| 13 | 2010 | David R. Crockford, Vice President, Clinical and Regulatory Affairs | 210.2K | 2.0K | — | 15.3K | — | 10.3K | 237.8K | 6.43% | ↗ |
| 14 | 2010 | C. Neil Lyons, Chief Financial Officer | 202.5K | 2.0K | — | 15.3K | — | 6.9K | 226.7K | 6.74% | ↗ |
| 15 | 2009 | J.J. Finkelstein, President and Chief Executive Officer | 244.6K | 18.7K | — | 116.2K | — | 13.0K | 392.5K | 29.60% | ↗ |
| 16 | 2009 | Mr. J.J. Finkelstein, President and Chief Executive Officer | 244.6K | 18.7K | — | 116.2K | — | 13.0K | 392.5K | 29.60% | ↗ |
| 17 | 2009 | Mr. C. Neil Lyons, Chief Financial Officer | 167.1K | 11.1K | — | 74.4K | — | 5.0K | 257.6K | 28.88% | ↗ |
| 18 | 2009 | C. Neil Lyons, Chief Financial Officer | 167.1K | 11.1K | — | 74.4K | — | 5.0K | 257.6K | 28.88% | ↗ |
| 19 | 2009 | Mr. David R. Crockford, Vice President, Clinical and Regulatory Affairs | 210.2K | 5.8K | — | — | — | 6.8K | 222.8K | 0.00% | ↗ |
| 20 | 2009 | David R. Crockford, Vice President, Clinical and Regulatory Affairs | 210.2K | 5.8K | — | — | — | 6.8K | 222.8K | 0.00% | ↗ |
| 21 | 2008 | Mr. J.J. Finkelstein, President and Chief Executive Officer | 299.5K | 22.5K | — | 86.1K | 15.0K | 17.7K | 440.8K | 19.54% | ↗ |
| 22 | 2008 | Mr. C. Neil Lyons, Chief Financial Officer | 200.8K | 12.2K | — | 68.8K | 10.1K | 8.5K | 300.5K | 22.91% | ↗ |
| 23 | 2008 | Mr. David R. Crockford, Vice President, Clinical and Regulatory Affairs | 209.2K | 12.6K | — | 51.7K | 10.5K | 11.7K | 295.7K | 17.48% | ↗ |
| 24 | 2007 | Mr. J.J. Finkelstein, President and Chief Executive Officer | 299.5K | 22.5K | — | 116.8K | 22.5K | 17.3K | 478.6K | 24.41% | ↗ |
| 25 | 2007 | Mr. C. Neil Lyons, Chief Financial Officer | 194.4K | 11.8K | — | 145.4K | 11.8K | 7.3K | 370.7K | 39.23% | ↗ |
| 26 | 2007 | Mr. David R. Crockford, Vice President, Clinical and Regulatory Affairs | 202.8K | 12.2K | — | 120.6K | 12.2K | 11.4K | 359.3K | 33.56% | ↗ |
| 27 | 2006 | J.J. Finkelstein, Chief Executive Officer | 288.0K | 15.0K | — | 72.5K | — | 16.0K | 391.5K | 18.52% | ↗ |
| 28 | 2006 | Neil Lyons, Chief Financial Officer | 182.1K | 9.5K | — | 118.8K | — | 7.3K | 317.6K | 37.42% | ↗ |
| 29 | 2006 | David Crockford, VP Clinical and Regulatory Affairs | 192.7K | 9.8K | — | 72.5K | — | 10.6K | 285.6K | 25.39% | ↗ |
| 30 | 2005 | J.J. Finkelstein, President and Chief Executive Officer | 235.0K | 25.0K | — | 100.0K | — | — | 360.0K | 27.78% | ↗ |
| 31 | 2005 | C. Neil Lyons, Chief Financial Officer and Treasurer | 116.9K | 11.7K | — | 200.0K | — | — | 328.6K | 60.87% | ↗ |
| 32 | 2005 | David R. Crockford, Vice President Clinical and Regulatory Affairs | 145.8K | 17.5K | — | 125.0K | — | 28.3K | 316.6K | 39.48% | ↗ |
| 33 | 2005 | Allan L. Goldstein, Chairman and Chief Scientific Advisor | 155.0K | 25.0K | — | 100.0K | — | — | 280.0K | 35.71% | ↗ |
| 34 | 2004 | J.J. Finkelstein, President and Chief Executive Officer | 200.0K | 25.0K | — | — | — | — | 225.0K | 0.00% | ↗ |
| 35 | 2004 | Allan L. Goldstein, Chairman and Chief Scientific Advisor | 125.0K | 25.0K | — | — | — | — | 150.0K | 0.00% | ↗ |
| 36 | 2003 | J.J. Finkelstein, President and Chief Executive Officer | 175.0K | — | — | — | — | — | 175.0K | 0.00% | ↗ |
| 37 | 2003 | Allan L. Goldstein, Chairman and Chief Scientific Advisor | 110.0K | — | — | — | — | — | 110.0K | 0.00% | ↗ |
| 38 | 2002 | J.J. Finkelstein, President and Chief Executive Officer | 175.0K | 20.0K | — | 500.0K | — | — | 695.0K | 71.94% | ↗ |
| 39 | 2002 | Allan L. Goldstein, Chairman and Chief Scientific Advisor | 110.0K | 20.0K | — | 300.0K | — | 37.7K | 467.7K | 64.15% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Allan L. Goldstein | Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board | 86.5K | — |
| J. J. Finkelstein | President, Chief Executive Officer & Director | 75.3K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RGRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
